Metformin inhibits inflammatory angiogenesis in a murine sponge model

Biomedicine and Pharmacotherapy

Volumn 64, Issue 3, 2010, Pages 220-225

  Xavier, D O ^a   Amaral, L S ^a   Gomes, M A ^a   Rocha, M A ^a   Campos, P R ^a   Cota, B D C V ^a   Tafuri, L S A ^a   Paiva, A M R ^a   Silva, J H ^a   Andrade, S P ^a   Belo, A V ^a  

^a FUMEC UNIVERSITY   (Brazil)

Author keywords

CCL2(MCP1 JE) collagen; Implant; TGF ; TNF ; VEGF

Indexed keywords

ACETYLGLUCOSAMINIDASE; COLLAGEN; CYTOKINE; HEMOGLOBIN; METFORMIN; MYELOPEROXIDASE; POLYESTER; POLYURETHAN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWISS WEBSTER MOUSE; VASCULAR TISSUE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; COLLAGEN; DRUG EVALUATION, PRECLINICAL; FOREIGN-BODY REACTION; INFLAMMATION; MALE; METFORMIN; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEROXIDASE; SURGICAL SPONGES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77649232560     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.08.004     Document Type: Article

References (36)

1. Araújo FA, Rocha MA, Andrade SP. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-α and TGF-β1. (epub ahead of print).
2. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent dibetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333 (1995) 541-549
3. Witters L.A. The blooming of the French lilac. J Clin Invest 108 (2001) 1105-1107
4. Molavi B., Rassouli N., Bagwe S., and Rasouli N. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag 3 6 (2007) 967-973
5. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: an update. Ann Intern Med 137 1 (2002) 25-33
6. Isoda K., Young J.L., Zirlik A., et al. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26 (2006) 611-617
7. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, et al. Metformin decreases angiogenesis via NF-kB and Erk1/2/Erk5 pathways by increasing antiangiogenic thrombospodin-1. Cardiovasc Res 2009;83(3):566-74.
8. Morin-Papunen L., Rautio K., Ruokonen A., Heldberg P., Puukka M., and Tapanainen J.S. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4649-4654
9. Takemura Y., Osuga Y., Yoshino O., et al. Metformin suppresses interleukin (IL)-1β-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 92 (2007) 3213-3218
10. Li L., Mamputu J.C., Wiernsperger N., and Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 54 (2005) 2227-2234
11. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., and Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66 21 (2006) 10269-10273
12. Sahra I.B., Laurent K., Loubat A., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27 (2008) 3576-3586
13. Buzzai M., Jones R.G., Amaravadi R.K., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67 14 (2007) 6745-6752
14. min/+ mice. Cancer Sci 99 11 (2008) 2136-2141
15. Hawley S.A., Gadalla A.E., Olsen G.S., and Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 (2002) 2420-2425
16. Towler M.C., and Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100 (2007) 328-341
17. Zou M.H., and Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 35 (2008) 535-545
18. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AM∅-activated protein kinase. Nature 415 (2002) 339-343
19. Hattori Y., Suzuki K., Hattori S., and Kasai K. Metformin inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 47 (2006) 1183-1188
20. Cavaillon J.M. Cytokines and macrophages. Biomed Pharmacother 48 10 (1994) 445-453
21. Andrade S.P., Machado R.D.P., Teixeira A.S., Belo A.V., Tarso A.M., and Beraldo W.T. Sponge-induced angiogenesis in mice and the pharmacological reactivity of the neovasculature quantitated by a fluorimetric method. Microvasc Res 54 (1997) 253-261
22. Belo AV, Barcelos LS, Ferreira MAND, Teixeira MM, Andrade SP. Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice. Life Sci 74:2827-2837.
23. Bergheim I., Luyendyk J.P., Steele C., et al. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther 316 (2006) 1053-1061
24. Heishi M., Hayashi K., Ichihara J., et al. Comparison of gene expression changes induced by biguanides in db/db mice liver. J Toxicol Sci 33 (2008) 339-347
25. Ferreira M.A.N.D., Barcelos L.S., Campos P.P., Vasconcelos A.C., Teixeira M.M., and Andrade S.P. Sponge-induced angiogenesis and inflammation in PAF receptor-deficient mice (PAFR-KO). Br J Pharmacol 141 (2004) 1185-1192
26. Campos P.P., Bakhle Y.S., and Andrade S.P. Mechanisms of wound healing responses in lupus-prone New Zealand White mouse strain. Wound Rep Reg 16 3 (2008) 416-424
27. Dvorak H.F. Vascular permeability factor/Vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 21 (2002) 4368-4380
28. Appleton I., Brown N.J., Willis D., et al. The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis. J Pathol 180 (1996) 90-94
29. Chen H.X., Gore-Langton R.E., and Cheson B.D. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 15 (2001) 1023-1026
30. Ikeda E., Achen M.G., Breier G., and Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270 (1995) 19761-19766
31. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
32. Nagata D., Mogi M., and Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 278 (2003) 31000-31006
33. Ouchi N., Shibata R., and Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 96 (2005) 838-846
34. Phoenix K.N., Vumbaca F., and Claffey K.P. Therapeutic metformin/AMPK activation promotes angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat (2008) 113(1):101-11
35. Bulcão C., Ribeiro-Filho F.F., Sañudo A., and Roberta Ferreira S.G. No effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 7 3 (2007) 219-224
36. Bergheim I., Guo L., and Davis M.A. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 130 (2006) 2099-2112